```
=> d his

     (FILE 'HOME' ENTERED AT 16:33:18 ON 18 DEC 2007)

     FILE 'REGISTRY' ENTERED AT 16:33:44 ON 18 DEC 2007
               ACTIVATE A10520506/L
               ---------
L1   (         1)SEA FILE=CAPLUS ABB=ON  PLU=ON  US2005-520506/AP
L2               SEL  PLU=ON  L1 1- RN :      24 TERMS
L3   (        24)SEA FILE=REGISTRY ABB=ON  PLU=ON  L2
L4   (         1)SEA FILE=REGISTRY ABB=ON  PLU=ON  646482-93-1/RN
L5   (         2)SEA FILE=CAPLUS ABB=ON  PLU=ON  L4
L6   (         1)SEA FILE=PROUSDDR ABB=ON  PLU=ON  L4
L7   (         1)SEA FILE=SYNTHLINE ABB=ON  PLU=ON  L4
L8   (         1)SEA FILE=TOXCENTER ABB=ON  PLU=ON  L4
L9   (         3)SEA FILE=USPATFULL ABB=ON  PLU=ON  L4
L10  (         0)SEA FILE=USPATOLD ABB=ON  PLU=ON  L4
L11  (         0)SEA FILE=USPAT2 ABB=ON  PLU=ON  L4
L12  (         8)SEA L4
L13  (         1)SEA FILE=CAPLUS ABB=ON  PLU=ON  L5 AND TUBERCULOSIS
L14  (         0)SEA FILE=PROUSDDR ABB=ON  PLU=ON  L6 AND TUBERCULOSIS
L15  (         0)SEA FILE=SYNTHLINE ABB=ON  PLU=ON  L7 AND TUBERCULOSIS
L16  (         0)SEA FILE=TOXCENTER ABB=ON  PLU=ON  L8 AND TUBERCULOSIS
L17  (         2)SEA FILE=USPATFULL ABB=ON  PLU=ON  L9 AND TUBERCULOSIS
L18  (         0)SEA FILE=USPATOLD ABB=ON  PLU=ON  L10 AND TUBERCULOSIS
L19  (         0)SEA FILE=USPAT2 ABB=ON  PLU=ON  L11 AND TUBERCULOSIS
L20  (         3)SEA L12 AND TUBERCULOSIS
               ---------
L21            1 S L12 NOT L20

     FILE 'CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL, USPATOLD,
     USPAT2' ENTERED AT 16:37:24 ON 18 DEC 2007
L22            2 S L12 NOT L20

     FILE 'REGISTRY' ENTERED AT 16:39:20 ON 18 DEC 2007
               E  646482-93-1/RN
L23            1 S E3

     FILE 'CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL' ENTERED AT
     16:40:34 ON 18 DEC 2007
L24           10 S L23
               SAVE TEMP ALL B10520506/L

     FILE 'REGISTRY' ENTERED AT 16:45:55 ON 18 DEC 2007
               E 646482-95-3/RN
L25            1 S E3
               E 646482-93-1/RN
L26            1 S E3
               E 646482-91-9/RN
L27            1 S E3
               E 646482-91-9/RN
L28            1 S E3
               E 646482-89-5/RN
L29            1 S E3
               E 646482-87-3/RN
L30            1 S E3
               E 646482-85-1/RN
L31            1 S E3
```

```
                E 646482-87-3/RN
L32           1 S E3
                E 646482-83-9
L33           1 S E3
                E 646482-81-7
L34           1 S E3

     FILE 'CA, MEDLINE, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL,
     USPATOLD, USPAT2' ENTERED AT 16:53:50 ON 18 DEC 2007
L35          23 S L25-L31 OR L33-L34
L36          23 S L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L33 OR L34
L37           7 S L36 AND TUBERCULOSIS
L38          13 DUP REM L37 L36 (17 DUPLICATES REMOVED)
L39           5 DUP REM L37 (2 DUPLICATES REMOVED)
L40          13 DUP REM L36 (10 DUPLICATES REMOVED)
L41           8 S L40 NOT L39
                SAVE TEMP ALL B10520506/L
```

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:41263 CAPLUS
DOCUMENT NUMBER: 140:105235
TITLE: Methods of treating microbial infections in humans and animals using a compound that interferes with microbial energy metabolism
INVENTOR(S): Townsend, Craig A.; Dick, James D.; Parrish, Nicole M.; Hughes, Minerva Amorette
PATENT ASSIGNEE(S): Fasgen, LLC, USA; The Johns Hopkins University
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004004712	A1	20040115	WO 2003-US21469		20030709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2491573	A1	20040115	CA 2003-2491573		20030709
AU 2003248896	A1	20040123	AU 2003-248896		20030709
EP 1539147	A1	20050615	EP 2003-763401		20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1671384	A	20050921	CN 2003-818521		20030709
JP 2005533834	T	20051110	JP 2004-520072		20030709
MX 2005PA00361	A	20050920	MX 2005-PA361		20050106
US 2006135568	A1	20060622	US 2005-520506		20051101 <--
PRIORITY APPLN. INFO.:			US 2002-394573P	P	20020709
			WO 2003-US21469	W	20030709

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 1 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646483-11-6 REGISTRY
ED Entered STN: 05 Feb 2004
CN Acetic acid, [(2,5-dihydro-2-methyl-2-octyl-5-oxo-3-thienyl)oxy]- (9CI) (CA INDEX NAME)
MF C15 H24 O4 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646483-10-5 REGISTRY
ED Entered STN: 05 Feb 2004
CN Acetic acid, [(2,5-dihydro-2-methyl-2-octyl-5-oxo-3-thienyl)oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
MF C19 H32 O4 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646483-08-1 REGISTRY
ED Entered STN: 05 Feb 2004
CN 2(5H)-Thiophenone, 4-hydroxy-5-methyl-5-octyl- (CA INDEX NAME)
OTHER NAMES:
CN 4-Hydroxy-5-methyl-5-octyl-5H-thiophen-2-one
MF C13 H22 O2 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 4 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646483-06-9 REGISTRY
ED Entered STN: 05 Feb 2004
CN Decanoic acid, 2-(acetylthio)-2-methyl-, ethyl ester (CA INDEX NAME)
MF C15 H28 O3 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 5 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646483-04-7 REGISTRY
ED Entered STN: 05 Feb 2004
CN Decanoic acid, 2-mercapto-2-methyl-, ethyl ester (CA INDEX NAME)
MF C13 H26 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 6 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646483-02-5 REGISTRY
ED Entered STN: 05 Feb 2004
CN 1,3-Oxathiolan-5-one, 2-(1,1-dimethylethyl)-4-methyl-4-octyl-, (2R,4R)-rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
DR 870829-06-4
MF C16 H30 O2 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 7 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646483-00-3 REGISTRY
ED Entered STN: 05 Feb 2004
CN Carbamic acid, 2-propenyl-, 2-[[[(2R,3S)-tetrahydro-4-methylene-2-octyl-5-oxo-3-furanyl]carbonyl]amino]ethyl ester, rel- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H32 N2 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 8 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-98-6 REGISTRY
ED Entered STN: 05 Feb 2004
CN Acetamide, N-(2-chloroethyl)-2-(decylsulfonyl)- (CA INDEX NAME)
MF C14 H28 Cl N O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 9 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-95-3 REGISTRY
ED Entered STN: 05 Feb 2004
CN Glycine, N-[(decylsulfonyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)
MF C15 H29 N O5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



VIII

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 10 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-93-1 REGISTRY
ED Entered STN: 05 Feb 2004
CN Acetic acid, [(2,5-dihydro-2-methyl-2-octyl-5-oxo-3-thienyl)oxy]-,
2-(4-chlorophenyl)hydrazide (9CI) (CA INDEX NAME)
MF C21 H29 Cl N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL



VII

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 11 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-91-9 REGISTRY
ED Entered STN: 05 Feb 2004
CN Acetic acid, (decylsulfonyl)-, 2-(4-chlorophenyl)hydrazide (9CI) (CA INDEX NAME)
MF C18 H29 Cl N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



VI

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 12 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-89-5 REGISTRY
ED Entered STN: 05 Feb 2004

CN 2-Furancarboxylic acid, 2-[[(2,5-dihydro-2-methyl-2-octyl-5-oxo-3-thienyl)oxy]acetyl]hydrazide (9CI) (CA INDEX NAME)
MF C20 H28 N2 O5 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



V

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 13 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-87-3 REGISTRY
ED Entered STN: 05 Feb 2004
CN 2-Furancarboxylic acid, 2-[(decylsulfonyl)acetyl]hydrazide (9CI) (CA INDEX NAME)
MF C17 H28 N2 O5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



IV

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 14 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-85-1 REGISTRY
ED Entered STN: 05 Feb 2004
CN 3-Furancarboxamide, tetrahydro-4-methylene-2-octyl-5-oxo-N-2-propen-1-yl-, (2R,3S)-rel- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3-Furancarboxamide, tetrahydro-4-methylene-2-octyl-5-oxo-N-2-propenyl-, (2R,3S)-rel- (9CI)
OTHER NAMES:
CN FAS 231
FS STEREOSEARCH
MF C17 H27 N O3
SR CA

LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Relative stereochemistry.



111

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 15 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-83-9 REGISTRY
ED Entered STN: 05 Feb 2004
CN 4-Pyridinecarboxylic acid, 2-[(decylsulfonyl)acetyl]hydrazide (9CI) (CA INDEX NAME)
MF C18 H29 N3 O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



11

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 16 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 646482-81-7 REGISTRY
ED Entered STN: 05 Feb 2004
CN Oxazole, 2-[(decylsulfonyl)methyl]-4,5-dihydro- (CA INDEX NAME)
MF C14 H27 N O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



1

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 17 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 218137-86-1 REGISTRY
ED Entered STN: 27 Jan 1999
CN 3-Furancarboxylic acid, tetrahydro-4-methylene-2-octyl-5-oxo- (CA INDEX NAME)
OTHER NAMES:
CN C 75
CN C 75 (enzyme inhibitor)
MF C14 H22 O4
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, IMSDRUGNEWS, IMSRESEARCH, RTECS*, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

56 REFERENCES IN FILE CA (1907 TO DATE)
56 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 18 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 116156-35-5 REGISTRY
ED Entered STN: 03 Sep 1988
CN 2(3H)-Oxazolone, 3,3',3''-phosphinylidynetris- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 620147
MF C9 H6 N3 O7 P
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 19 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 25952-53-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1,3-Propanediamine, N3-(ethylcarbonimidoyl)-N1,N1-dimethyl-, hydrochloride (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochloride (9CI)
CN Carbodiimide, [3-(dimethylamino)propyl]ethyl-, monohydrochloride (8CI)
OTHER NAMES:
CN 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
CN 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride
CN 1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride
CN 1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide monohydrochloride
CN 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
CN 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide monohydrochloride
CN 3-[3-(Dimethylamino)propyl]-1-ethylcarbodiimide hydrochloride
CN EDAP
CN EDC
CN EDC (coupling agent)
CN EDCI
CN N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
CN N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride
CN WSC
CN [3-(Dimethylamino)propyl]ethylcarbodiimide hydrochloride
AR 7084-11-9
DR 93128-40-6
MF C8 H17 N3 . Cl H
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (1892-57-5)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1952 REFERENCES IN FILE CA (1907 TO DATE)
78 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1958 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 20 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 5435-83-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Acetic acid, (decylsulfonyl)- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN NSC 21509
MF C12 H24 O4 S
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 21 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 1073-70-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN Hydrazine, (4-chlorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydrazine, (4-chlorophenyl)-, monohydrochloride (9CI)
CN Hydrazine, (p-chlorophenyl)-, monohydrochloride (8CI)
OTHER NAMES:
CN 4-Chlorophenylhydrazine hydrochloride
CN 4-Chlorophenylhydrazine monohydrochloride
CN p-Chlorophenylhydrazine hydrochloride
CN p-Chlorophenylhydrazine monohydrochloride
MF C6 H7 Cl N2 . Cl H
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (1073-69-4)



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

274 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
275 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L3 ANSWER 22 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 870-24-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Ethanamine, 2-chloro-, hydrochloride (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanamine, 2-chloro-, hydrochloride (9CI)
CN Ethylamine, 2-chloro-, hydrochloride (6CI, 7CI, 8CI)
OTHER NAMES:
CN β-Chloroethylamine hydrochloride
CN 1-Amino-2-chloroethane hydrochloride
CN 2-Aminoethyl chloride hydrochloride
CN 2-Chloroethanamine hydrochloride
CN 2-Chloroethylamine hydrochloride
CN 2-Chloroethylamine monohydrochloride
MF C2 H6 Cl N . Cl H
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, GMELIN*, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, PS, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (689-98-5)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

590 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
590 REFERENCES IN FILE CAPLUS (1907 TO DATE)
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L3 ANSWER 23 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 530-62-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Methanone, di-1H-imidazol-1-yl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazole, 1,1'-carbonylbis- (9CI)
CN Imidazole, 1,1'-carbonyldi- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 1,1'-Carbonylbis-1H-imidazole
CN 1,1'-Carbonylbisimidazole

CN 1,1'-Carbonyldiimidazole
CN 1-(1H-Imidazol-1-ylcarbonyl)-1H-imidazole
CN Bis(imidazol-1-yl) ketone
CN Bis(imidazol-1-yl)methanone
CN Diimidazol-1-yl ketone
CN N,N'-Carbonylbis(imidazole)
CN N,N'-Carbonyldiimidazole
CN N,N-Carbonyldiimidazole
CN NSC 67203
DR 128456-94-0
MF C7 H6 N4 O
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, PS, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3105 REFERENCES IN FILE CA (1907 TO DATE)
126 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3110 REFERENCES IN FILE CAPLUS (1907 TO DATE)
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L3 ANSWER 24 OF 24 REGISTRY COPYRIGHT 2007 ACS on STN
RN 56-65-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN Adenosine 5'-(tetrahydrogen triphosphate) (CA INDEX NAME)
OTHER NAMES:
CN 5'-ATP
CN Adenosine 5'-triphosphate
CN Adenosine 5'-triphosphoric acid
CN Adenosine triphosphate
CN Adenosine, 5'-(tetrahydrogen triphosphate)
CN Adenylpyrophosphoric acid
CN Adephos
CN Adetol
CN Adynol
CN Atipi
CN ATP
CN ATP (nucleotide)
CN Atriphos
CN Cardenosine
CN Fosfobion
CN Glucobasin

CN Myotriphos
CN Phosphobion
CN Striadyne
CN Triadenyl
CN Triphosphaden
CN Triphosphoric acid adenosine ester
FS STEREOSEARCH
DR 896506-78-8, 10168-83-9, 16488-07-6, 51569-41-6, 71800-44-7, 84412-18-0
MF C10 H16 N5 O13 P3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NAPRALERT, PHAR, PIRA, PROMT, PS, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, TULSA, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



```
=> s e3
L4            1 646482-93-1/RN

=> d l4

L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   646482-93-1  REGISTRY
ED   Entered STN:  05 Feb 2004
CN   Acetic acid, [(2,5-dihydro-2-methyl-2-octyl-5-oxo-3-thienyl)oxy]-,
     2-(4-chlorophenyl)hydrazide (9CI)  (CA INDEX NAME)
MF   C21 H29 Cl N2 O3 S
SR   CA
LC   STN Files:   CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             2 REFERENCES IN FILE CA (1907 TO DATE)
             2 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:41263 CAPLUS
DOCUMENT NUMBER: 140:105235
TITLE: Methods of treating microbial infections in humans and animals using a compound that interferes with microbial energy metabolism
INVENTOR(S): Townsend, Craig A.; Dick, James D.; Parrish, Nicole M.; Hughes, Minerva Amorette
PATENT ASSIGNEE(S): Fasgen, LLC, USA; The Johns Hopkins University
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004712	A1	20040115	WO 2003-US21469	20030709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491573	A1	20040115	CA 2003-2491573	20030709
AU 2003248896	A1	20040123	AU 2003-248896	20030709
EP 1539147	A1	20050615	EP 2003-763401	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671384	A	20050921	CN 2003-818521	20030709
JP 2005533834	T	20051110	JP 2004-520072	20030709
MX 2005PA00361	A	20050920	MX 2005-PA361	20050106
US 2006135568	A1	20060622	US 2005-520506	20051101
PRIORITY APPLN. INFO.:			US 2002-394573P P	20020709
			WO 2003-US21469 W	20030709

AB A method of treating a subject with a microbially-based infection, comprising the administration of a compound to the subject. The compound is able to decrease ATP levels in the microbe by at least 10% compared to controls after 24 h in an in vitro test, without killing mammalian cells during the same time period. The decrease in ATP levels is measured by: (1) removing the cells from the testing location and putting them on ice; (2) harvesting the cells at 4° by centrifugation and disrupting it with bead-beating in an ATP extraction buffer; (3) removing cellular debris by centrifugation at 4°, leaving an ATP-containing supernatant; (4) measuring the amount of ATP present in the supernatant by a bioluminescence assay at 4°.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Antimicrobial agents
Bos taurus
Capra
Energy metabolism, microbial
Equus caballus

Human
Infection
Leprosy
Mycobacterium avium paratuberculosis
Mycobacterium intracellulare
Mycobacterium leprae
Mycobacterium tuberculosis
Mycobacterium ulcerans
Ovis aries
Rhodococcus
Tuberculosis
(methods of treating microbial infections in humans and animals using compound that interferes with microbial energy metabolism)

IT 646482-93-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(methods of treating microbial infections in humans and animals using compound that interferes with microbial energy metabolism)

L6 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2006:289307 USPATFULL

TITLE: Novel compounds, pharmaceutical compositions containing same, and methods of use for same

INVENTOR(S): Kuhajda, Francis P., Baltimore, MD, UNITED STATES
Medghalchi, Susan M., Baltimore, MD, UNITED STATES
McFadden, Jill M., Baltimore, MD, UNITED STATES
Thupari, Jagan N., Baltimore, MD, UNITED STATES

PATENT ASSIGNEE(S): FASgen, Inc., Baltimore, MD, UNITED STATES, 21224 (U.S. corporation)
Johns Hopkins University, Baltimore, MD, UNITED STATES, 21224 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006247302	A1	20061102	
APPLICATION INFO.:	US 2003-520505	A1	20030709	(10)
	WO 2003-US21700		20030709	
			20060206	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-394585P	20020709 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: COVINGTON & BURLING, LLP, ATTN: PATENT DOCKETING, 1201 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC, 20004-2401, US
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 2264
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising a phamaceurtical diluent and a compound of formula IV wherein R.sup.21.dbd.H, C.sub.1-C.sub.20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, --CH.sub.2OR.sup.25, --C(O)R.sup.25, --CO(O)R.sup.25, --C(O)NR.sup.25R.sup.26, --CH.sub.2C(O)R.sup.25, or --CH.sup.2C(O)NHR.sub.25, where R.sub.25 and R.sub.26 are each independently H, C.sub.1-C.sub.10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R.sup.22 .dbd.--OH, --OR.sup.27, --OCH.sub.2C(O)R.sup.27, --OCH.sub.2C(O)NHR.sup.27, --OC(O)R.sup.27, --OC(O)OR.sup.27, --OC(O)NHNH--R.sup.5, or --OC(O)NR.sup.27R.sup.28, where R.sup.27 and R.sup.28 are each independently H, C.sub.1-C.sub.20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R.sup.27 and R.sup.28 can each optionally contain halogen atoms; R.sup.23 and R.sup.24, the same or different from each other, are C.sub.1-C.sub.20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . some in vitro activity has been shown against some bacteria, actinomycetes, and mycobacteria, although no activity was found against Mycobacterium tuberculosis. The activity of fatty acid synthesis inhibitors and cerulenin in particular has not been evaluated

against protozoa such as Toxoplasma. . .

SUMM . . . urogenital infection, especially if caused by Candida albicans or Trichomonas vaginalis; and (6) pulmonary disease, especially if caused by Mycobacterium tuberculosis, Aspergillus, or Pneumocystis carinii. Infectious organisms that are susceptible to treatment with fatty acid synthesis inhibitors include Mycobacterium tuberculosis, especially multiply-drug resistant strains, and protozoa such as Toxoplasma.

IT 88957-53-3P, 5-Benzyl-4-hydroxy-5-methyl-5H-thiophen-2-one 278597-52-7P 646482-89-5P 646482-93-1P 646483-08-1P, 4-Hydroxy-5-methyl-5-octyl-5H-thiophen-2-one 646483-10-5P 646483-11-6P 646517-37-5P 646517-38-6P 646517-39-7P 646517-40-0P, 4-Hydroxy-5-methyl-5-(2-methylbuta-1,3-dienyl)-5H-thiophen-2-one 646517-41-1P, 4-Hydroxy-5-methyl-5-hexyl-5H-thiophen-2-one 646517-42-2P, 4-Methoxy-5-methyl-5-octyl-5H-thiophen-2-one 646517-43-3P, 4-Methoxy-5-methyl-5-hexyl-5H-thiophen-2-one 646517-44-4P, 5-Benzyl-4-methoxy-5-methyl-5H-thiophen-2-one 646517-45-5P 646517-46-6P 646517-47-7P, 4-(4-Chlorobutoxy)-5-methyl-5-octyl-5H-thiophen-2-one 646517-48-8P, 4-(4-Chlorobutoxy)-5-methyl-5-hexyl-5H-thiophen-2-one 646517-49-9P, 4-Allyloxy-5-methyl-5-octyl-5H-thiophen-2-one 646517-50-2P, -4-Allyloxy-5-methyl-5-hexyl-5H-thiophen-2-one 646517-51-3P 646517-52-4P 646517-53-5P 646517-54-6P 646517-55-7P 646517-56-8P 646517-57-9P 646517-58-0P 646517-59-1P 646517-60-4P 646517-61-5P 646517-62-6P 646517-63-7P 646517-64-8P 646517-65-9P 646517-66-0P 646517-67-1P 646517-68-2P 646517-69-3P 646517-70-6P 646517-71-7P 646517-72-8P 646517-73-9P 646517-74-0P 646517-75-1P 646517-95-5P 646517-96-6P 646517-97-7P 646517-98-8P 646517-99-9P
(preparation of thiolactomycin analogs as inhibitors of fatty acid synthase, stimulators of CPT-1, and inhibitors of neuropeptide Y)

L6 ANSWER 3 OF 3 USPATFULL on STN

ACCESSION NUMBER:	2006:160031 USPATFULL
TITLE:	Methods of treating microbial infections in humans and animals
INVENTOR(S):	Townsend, Craig A., Baltimore, MD, UNITED STATES Dick, James D., Baltimore, MD, UNITED STATES Parrish, Nicole M., Ellicott City, MD, UNITED STATES Hughes, Minerva Amorette, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006135568	A1	20060622	
APPLICATION INFO.:	US 2003-520506	A1	20030709	(10)
	WO 2003-US21469		20030709	
			20051101	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-394573P	20020709 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	COVINGTON & BURLING, ATTN: PATENT DOCKETING, 1201 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC, 20004-2401, US
NUMBER OF CLAIMS:	27
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	7 Drawing Page(s)
LINE COUNT:	937

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating a subject with a microbially-based infection, comprising the administration of a compound to the subject. The compound is able to decrease ATP levels in the microbe by at least 10% compared to controls after 24 hours in an in vitro test, without killing mammalian cells during the same time period. The decrease in ATP levels is measured by: (1) removing the cells from the testing location and putting them on ice; (2) harvesting the cells at 4 degrees C. by centrifugation and disrupting it with bead-beating in an ATP extraction buffer; (3) removing cellular debris by centrifugation at 4 degrees C., leaving an ATP-containing supernatant; (4) measuring the amount of ATP present in the supernatant by a bioluminescence assay at 4 degrees C.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM Microbially-based infections remain a major public health issue in the United States and around the world. For example, tuberculosis remains a significant health problem in the U.S. and globally. Tuberculosis (TB) is the leading cause of death due to a single infectious agent in the world. It is believed that approximately 1.86 billion people or 32% of the world's population are infected with Mycobacterium tuberculosis (M. tb.) There are about 8 million new active cases of TB per year and approximately 2 million deaths. This. . .

SUMM . . . the standard first-line agents intensifies the need for the identification of new, novel targets and drug development. MDR-TB (multi-drug resistant tuberculosis) difficult and expensive to treat, as well as being associated with significantly higher mortality rates than drug-susceptible TB. In the. . .

SUMM A significant need exists for improved tuberculosis drugs with reduced toxicity, activity against MDR-TB, alternate mechanisms of action, and activity against latent disease. Despite advances in the prevention and treatment of tuberculosis over the past five decades, significant obstacles remain before control of this disease can be anticipated. Current standard of care. . .

DRWD FIG. 6 shows the potentiation of the inhibitory activity of OSA at low concentrations of ethanol (0.05%) against M. tuberculosis.

DETD . . . also upregulated during oxidative or detergent stress and bears masked similarity to the α-crystallin (acr) (14 kDa antigen) of M. tuberculosis (41% identity over 98 amino acids). The heat shock response is ubiquitous and allows cells to survive under both normal. . .

DETD Mycobacteria and growth conditions. Mycobacterium tuberculosis (H37Rv) M. bovis BCG (BCG, Pasteur strain, ATCC 35734) and M. smegmatis (mc.sup.2 6 1-2c) were used in this study.. . .

DETD . . . substrate, was determined using a modification of the standard BACTEC radiometric growth procedure (44). Briefly, inocula were prepared from M. tuberculosis cultures maintained on Lowenstein-Jensen agar slants (Difco, Detroit, Mich.) using glass beads and commercially available diluting fluid (Becton Dickinson, Sparks,. . .

DETD . . . to OSA in BCG. Previous investigators successfully used a similar approach to identify the enzymatic target of isoniazid in M. tuberculosis as described in Mdluli D., et al., "Inhibition of a Mycobacterium tuberculosis, β-ketoacyl ACP synthase by isoniazid," Science, 280:1607-1610 (1998). As shown in FIG. 2 (Right), treatment with OSA resulted in significant. . .

DETD . . . FIG. 6, 0.05% ethanol potentiated the effects of OSA on growth inhibition, reducing the MIC from 6.25 μg/ml in M. tuberculosis H37Rv to <1.5 μg/ml. No potentiation in activity was observed between ethanol and streptomycin. Previously we reported that treatment of. . .

CLM What is claimed is:

. . . The method of claim 1, wherein the subject is infected with a microbe selected from the group consisting of M. tuberculosis, M. avium-intracellulare, M. leprae, M. paratuberculosis, M. ulcerans, and Rhodococcus.

IT 646482-93-1P

(methods of treating microbial infections in humans and animals using a compound that interferes with microbial energy metabolism)